Deaths with COVID-19 and from all-causes following first-ever SARS-CoV-2 infection in individuals with preexisting mental disorders: A national cohort study from Czechia

(DOCX)

(DOCX)

(DOCX)

S1 Fig. Directed acyclic graph. S2 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 28 days in people with any mental disorder in epoch 1, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S3 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 28 days in people with any mental disorder in epoch 2, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S4 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 28 days in people with any mental disorder in epoch 3, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S5 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 28 days in people with any mental disorder in epoch 4, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S6 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 28 days in people with any mental disorder in epoch 5, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S7 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 28 days in people with any mental disorder in epoch 1, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S8 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 28 days in people with any mental disorder in epoch 2, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S9 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 28 days in people with any mental disorder in epoch 3, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S10 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 28 days in people with any mental disorder in epoch 4, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S11 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 28 days in people with any mental disorder in epoch 5, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S12 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 28 days in people with substance use disorders in epoch 1, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S13 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 28 days in people with substance use disorders in epoch 2, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S14 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 28 days in people with substance use disorders in epoch 3, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S15 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 28 days in people with substance use disorders in epoch 4, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S16 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 28 days in people with substance use disorders in epoch 5, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S17 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 28 days in people with substance use disorders in epoch 1, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S18 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 28 days in people with substance use disorders in epoch 2, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S19 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 28 days in people with substance use disorders in epoch 3, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S20 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 28 days in people with substance use disorders in epoch 4, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S21 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 28 days in people with substance use disorders in epoch 5, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S22 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 28 days in people with psychotic disorders in epoch 1, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S23 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 28 days in people with psychotic disorders in epoch 2, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S24 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 28 days in people with psychotic disorders in epoch 3, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S25 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 28 days in people with psychotic disorders in epoch 4, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S26 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 28 days in people with psychotic disorders in epoch 5, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S27 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 28 days in people with psychotic disorders in epoch 1, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S28 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 28 days in people with psychotic disorders in epoch 2, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S29 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 28 days in people with psychotic disorders in epoch 3, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S30 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 28 days in people with psychotic disorders in epoch 4, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S31 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 28 days in people with psychotic disorders in epoch 5, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S32 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 28 days in people with affective disorders in epoch 1, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S33 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 28 days in people with affective disorders in epoch 2, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S34 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 28 days in people with affective disorders in epoch 3, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S35 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 28 days in people with affective disorders in epoch 4, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S36 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 28 days in people with affective disorders in epoch 5, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S37 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 28 days in people with affective disorders in epoch 1, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S38 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 28 days in people with affective disorders in epoch 2, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S39 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 28 days in people with affective disorders in epoch 3, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S40 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 28 days in people with affective disorders in epoch 4, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S41 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 28 days in people with affective disorders in epoch 5, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S42 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 28 days in people with anxiety disorders in epoch 1, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S43 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 28 days in people with anxiety disorders in epoch 2, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S44 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 28 days in people with anxiety disorders in epoch 3, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S45 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 28 days in people with anxiety disorders in epoch 4, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S46 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 28 days in people with anxiety disorders in epoch 5, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S47 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 28 days in people with anxiety disorders in epoch 1, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S48 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 28 days in people with anxiety disorders in epoch 2, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S49 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 28 days in people with anxiety disorders in epoch 3, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S50 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 28 days in people with anxiety disorders in epoch 4, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S51 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 28 days in people with anxiety disorders in epoch 5, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S52 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 60 days in people with any mental disorder in epoch 1, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S53 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 60 days in people with any mental disorder in epoch 2, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S54 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 60 days in people with any mental disorder in epoch 3, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S55 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 60 days in people with any mental disorder in epoch 4, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S56 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 60 days in people with any mental disorder in epoch 5, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S57 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 60 days in people with any mental disorder in epoch 1, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S58 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 60 days in people with any mental disorder in epoch 2, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S59 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 60 days in people with any mental disorder in epoch 3, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S60 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 60 days in people with any mental disorder in epoch 4, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S61 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 60 days in people with any mental disorder in epoch 5, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S62 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 60 days in people with substance use disorders in epoch 1, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S63 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 60 days in people with substance use disorders in epoch 2, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S64 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 60 days in people with substance use disorders in epoch 3, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S65 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 60 days in people with substance use disorders in epoch 4, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S66 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 60 days in people with substance use disorders in epoch 5, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S67 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 60 days in people with substance use disorders in epoch 1, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S68 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 60 days in people with substance use disorders in epoch 2, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S69 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 60 days in people with substance use disorders in epoch 3, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S70 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 60 days in people with substance use disorders in epoch 4, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S71 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 60 days in people with substance use disorders in epoch 5, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S72 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 60 days in people with psychotic disorders in epoch 1, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S73 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 60 days in people with psychotic disorders in epoch 2, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S74 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 60 days in people with psychotic disorders in epoch 3, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S75 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 60 days in people with psychotic disorders in epoch 4, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S76 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 60 days in people with psychotic disorders in epoch 5, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S77 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 60 days in people with psychotic disorders in epoch 1, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S78 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 60 days in people with psychotic disorders in epoch 2, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S79 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 60 days in people with psychotic disorders in epoch 3, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S80 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 60 days in people with psychotic disorders in epoch 4, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S81 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 60 days in people with psychotic disorders in epoch 5, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S82 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 60 days in people with affective disorders in epoch 1, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S83 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 60 days in people with affective disorders in epoch 2, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S84 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 60 days in people with affective disorders in epoch 3, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S85 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 60 days in people with affective disorders in epoch 4, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S86 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 60 days in people with affective disorders in epoch 5, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S87 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 60 days in people with affective disorders in epoch 1, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S88 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 60 days in people with affective disorders in epoch 2, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S89 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 60 days in people with affective disorders in epoch 3, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S90 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 60 days in people with affective disorders in epoch 4, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S91 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 60 days in people with affective disorders in epoch 5, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S92 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 60 days in people with anxiety disorders in epoch 1, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S93 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 60 days in people with anxiety disorders in epoch 2, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S94 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 60 days in people with anxiety disorders in epoch 3, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S95 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 60 days in people with anxiety disorders in epoch 4, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S96 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 60 days in people with anxiety disorders in epoch 5, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S97 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 60 days in people with anxiety disorders in epoch 1, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S98 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 60 days in people with anxiety disorders in epoch 2, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S99 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 60 days in people with anxiety disorders in epoch 3, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S100 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 60 days in people with anxiety disorders in epoch 4, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S101 Fig. Cumulative probability with 95% confidence interval of death with COVID-19 up to 60 days in people with anxiety disorders in epoch 5, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S102 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 28 days in people with any mental disorder in epoch 1, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S103 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 28 days in people with any mental disorder in epoch 2, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S104 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 28 days in people with any mental disorder in epoch 3, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S105 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 28 days in people with any mental disorder in epoch 4, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S106 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 28 days in people with any mental disorder in epoch 5, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S107 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 28 days in people with any mental disorder in epoch 1, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S108 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 28 days in people with any mental disorder in epoch 2, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S109 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 28 days in people with any mental disorder in epoch 3, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S110 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 28 days in people with any mental disorder in epoch 4, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S111 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 28 days in people with any mental disorder in epoch 5, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S112 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 28 days in people with substance use disorders in epoch 1, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S113 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 28 days in people with substance use disorders in epoch 2, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S114 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 28 days in people with substance use disorders in epoch 3, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S115 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 28 days in people with substance use disorders in epoch 4, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S116 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 28 days in people with substance use disorders in epoch 5, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S117 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 28 days in people with substance use disorders in epoch 1, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S118 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 28 days in people with substance use disorders in epoch 2, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S119 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 28 days in people with substance use disorders in epoch 3, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S120 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 28 days in people with substance use disorders in epoch 4, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S121 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 28 days in people with substance use disorders in epoch 5, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S122 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 28 days in people with psychotic disorders in epoch 1, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S123 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 28 days in people with psychotic disorders in epoch 2, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S124 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 28 days in people with psychotic disorders in epoch 3, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S125 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 28 days in people with psychotic disorders in epoch 4, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S126 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 28 days in people with psychotic disorders in epoch 5, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S127 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 28 days in people with psychotic disorders in epoch 1, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S128 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 28 days in people with psychotic disorders in epoch 2, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S129 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 28 days in people with psychotic disorders in epoch 3, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S130 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 28 days in people with psychotic disorders in epoch 4, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S131 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 28 days in people with psychotic disorders in epoch 5, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S132 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 28 days in people with affective disorders in epoch 1, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S133 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 28 days in people with affective disorders in epoch 2, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S134 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 28 days in people with affective disorders in epoch 3, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S135 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 28 days in people with affective disorders in epoch 4, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S136 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 28 days in people with affective disorders in epoch 5, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S137 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 28 days in people with affective disorders in epoch 1, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S138 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 28 days in people with affective disorders in epoch 2, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S139 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 28 days in people with affective disorders in epoch 3, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S140 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 28 days in people with affective disorders in epoch 4, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S141 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 28 days in people with affective disorders in epoch 5, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S142 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 28 days in people with anxiety disorders in epoch 1, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S143 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 28 days in people with anxiety disorders in epoch 2, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S144 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 28 days in people with anxiety disorders in epoch 3, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S145 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 28 days in people with anxiety disorders in epoch 4, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S146 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 28 days in people with anxiety disorders in epoch 5, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S147 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 28 days in people with anxiety disorders in epoch 1, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S148 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 28 days in people with anxiety disorders in epoch 2, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S149 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 28 days in people with anxiety disorders in epoch 3, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S150 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 28 days in people with anxiety disorders in epoch 4, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S151 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 28 days in people with anxiety disorders in epoch 5, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S152 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 60 days in people with any mental disorder in epoch 1, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S153 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 60 days in people with any mental disorder in epoch 2, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S154 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 60 days in people with any mental disorder in epoch 3, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S155 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 60 days in people with any mental disorder in epoch 4, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S156 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 60 days in people with any mental disorder in epoch 5, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S157 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 60 days in people with any mental disorder in epoch 1, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S158 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 60 days in people with any mental disorder in epoch 2, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S159 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 60 days in people with any mental disorder in epoch 3, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S160 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 60 days in people with any mental disorder in epoch 4, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S161 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 60 days in people with any mental disorder in epoch 5, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S162 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 60 days in people with substance use disorders in epoch 1, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S163 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 60 days in people with substance use disorders in epoch 2, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S164 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 60 days in people with substance use disorders in epoch 3, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S165 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 60 days in people with substance use disorders in epoch 4, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S166 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 60 days in people with substance use disorders in epoch 5, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S167 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 60 days in people with substance use disorders in epoch 1, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S168 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 60 days in people with substance use disorders in epoch 2, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S169 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 60 days in people with substance use disorders in epoch 3, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S170 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 60 days in people with substance use disorders in epoch 4, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S171 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 60 days in people with substance use disorders in epoch 5, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S172 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 60 days in people with psychotic disorders in epoch 1, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S173 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 60 days in people with psychotic disorders in epoch 2, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S174 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 60 days in people with psychotic disorders in epoch 3, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S175 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 60 days in people with psychotic disorders in epoch 4, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S176 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 60 days in people with psychotic disorders in epoch 5, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S177 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 60 days in people with psychotic disorders in epoch 1, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S178 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 60 days in people with psychotic disorders in epoch 2, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S179 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 60 days in people with psychotic disorders in epoch 3, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S180 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 60 days in people with psychotic disorders in epoch 4, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S181 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 60 days in people with psychotic disorders in epoch 5, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S182 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 60 days in people with affective disorders in epoch 1, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S183 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 60 days in people with affective disorders in epoch 2, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S184 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 60 days in people with affective disorders in epoch 3, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S185 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 60 days in people with affective disorders in epoch 4, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S186 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 60 days in people with affective disorders in epoch 5, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S187 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 60 days in people with affective disorders in epoch 1, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S188 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 60 days in people with affective disorders in epoch 2, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S189 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 60 days in people with affective disorders in epoch 3, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S190 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 60 days in people with affective disorders in epoch 4, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S191 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 60 days in people with affective disorders in epoch 5, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S192 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 60 days in people with anxiety disorders in epoch 1, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S193 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 60 days in people with anxiety disorders in epoch 2, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S194 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 60 days in people with anxiety disorders in epoch 3, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S195 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 60 days in people with anxiety disorders in epoch 4, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S196 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 60 days in people with anxiety disorders in epoch 5, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes. S197 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 60 days in people with anxiety disorders in epoch 1, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S198 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 60 days in people with anxiety disorders in epoch 2, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S199 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 60 days in people with anxiety disorders in epoch 3, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S200 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 60 days in people with anxiety disorders in epoch 4, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes. S201 Fig. Cumulative probability with 95% confidence interval of all-cause mortality up to 60 days in people with anxiety disorders in epoch 5, cases ascertained by diagnosis per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes coupled with prescription for psychopharmaceuticals per the Anatomical Therapeutic Chemical (ATC) classification codes.

(ZIP)